- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
medmix Reports Resilient Performance with Strong Profit Gains in Challenging Markets
Company Delivers Improved Margins and Profitability Despite Lower Revenues
Published on Feb. 26, 2026
Got story updates? Submit your updates here. ›
medmix, a global leader in high-precision delivery devices, reported its full-year 2025 results, demonstrating resilience and focused execution amid global uncertainty. The company generated revenues of CHF 448 million, down 4.8% year-over-year on an organic basis, but improved its adjusted EBITDA margin to 20.0%, up 90 basis points. Net income increased to CHF 7.0 million from a loss of CHF 6.4 million in 2024, driven by higher gross profit and cost savings from the company's Growth and Efficiency program.
Why it matters
medmix's performance in 2025 highlights its ability to navigate challenging market conditions and maintain profitability through operational improvements and strategic initiatives. The company's pivot towards healthcare, with strong progress in its Surgery and Drug Delivery business units, as well as its continued leadership in Dental, demonstrate its resilience and adaptability. The company's commitment to shareholder value is reflected in its proposed dividend and revised mid-term financial targets.
The details
medmix's Healthcare segment revenue declined 1.0% year-over-year, but the Dental business unit delivered above-market growth of 5.9%. The Drug Delivery business unit saw a 19.6% decline due to customer dual sourcing, while the Surgery business unit grew 0.4%. In the Consumer & Industrial segment, the Industry business unit grew 1.4%, but the Beauty business unit declined 12.9% due to market weakness. The company's Growth and Efficiency program delivered CHF 22.6 million in cost savings over 2024 and 2025, exceeding its initial target.
- medmix generated revenues of CHF 448 million in 2025.
- The company's adjusted EBITDA margin increased to 20.0% in 2025, up 90 basis points year-over-year.
- Net income increased to CHF 7.0 million in 2025, compared to a loss of CHF 6.4 million in 2024.
- medmix's Growth and Efficiency program delivered CHF 22.6 million in cost savings over 2024 and 2025.
The players
medmix
A global leader in high-precision delivery devices, with leading positions in healthcare, consumer, and industrial end-markets.
René Willi
The CEO of medmix.
Sven Luginbühl
The newly appointed Chief Financial Officer of medmix, who previously served as the company's Deputy Group CFO.
Jennifer Dean
The former CFO of medmix, who will now lead the company's Beauty business unit.
What they’re saying
“In 2025, medmix demonstrated resilience, discipline, and focused execution amid global uncertainty. We have significantly improved our margin and profitability despite lower revenues.”
— René Willi, CEO (medmix)
What’s next
The company's Board of Directors will propose a dividend of CHF 0.10 per share at the Annual General Meeting on April 16, 2026.
The takeaway
medmix's performance in 2025 showcases its ability to adapt and thrive in challenging market conditions, with a focus on operational efficiency, strategic initiatives, and shareholder value creation. The company's pivot towards healthcare and its commitment to innovation and technological advancement position it well for continued success in the years ahead.
